AETC National Resource Center


	participating institutions: Johns Hopkins University AIDS Service, New York State DOH AIDS Institute, The CORE Center, Cook County Hospital

NEWS AND NEW DEVELOPMENTS

A Double-blind, Placebo-Controlled Trial of Testosterone Therapy for HIV-Positive Men with Hypogonadal Symptoms [JG Rabkin, et al. Arch Gen Psych 2000;57:141]: The authors enrolled 74 hypogonadal patients in a placebo-controlled trial of testosterone with biweekly injections versus placebo over six weeks with the option of open label treatment for an additional 18 weeks. Results are summarized in the following table:

Testosterone Therapy for Hypogonadal Men:
Results of a Double Blind-Placebo Controlled 6-Week Study

Testosterone
n = 38 Placebo
n = 32

Improved libido 74%* 19%

Improved fatigue 59%* 25%

Improved depression 58% 14%

Increased mm mass (mean) 1.6 kg* -

* P <0.05

Comment: This is an excellent study demonstrating the potential benefits of testosterone therapy in hypogonadal men with HIV infection. Testosterone may be one of the more important treatments to offer patients, but it is commonly overlooked, perhaps because it is not promoted aggressively by the pharmaceutical industry. posted 6/6/2000

previous article | next article

back to news table of contents

Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site because no single reference or service can take the place of medical training, education, and experience. Consumers are cautioned that this site is not intended to provide medical advice about any specific medical condition they may have or treatment they may need, and they are encouraged to call or see their physician or other health care provider promptly with any health related questions they may have.